combination with another PI; (2) to assess whether the concomitant administration of daily P. ostreatus and such regimens in this population is safe; and (3) to investigate the mechanism of action by which P. ostreatus may exert an antihyperlipidemic eff ect.
Pleurotus ostreatus was cloned and maintained in vitro at the spawn laboratories before being expanded into edible mushrooms. Clusters of young mushrooms were harvested and fl ash-frozen. We designed a single-arm, open-label study of 8 weeks' duration with a target enrollment of 20 subjects. Study participants (patients) with ritonavir-induced elevated LDL cholesterol levels (>160 mg/dL) were eligible to enroll. After screening and obtaining informed consent, patients were admitted to the inpatient General Clinical Research Center (GCRC) at San Francisco General Hospital for a one-night stay to obtain pretreatment PI blood levels. Patients were given their fi rst mushroom dose in the GCRC and then received packets of freeze-dried P. ostreatus (15 gm/day) to be administered orally each day for the 8-week trial period. Patients were followed with lipid levels drawn every 2 weeks to assess effi cacy. Safety assessments include a pharmacokinetic substudy to determine if P. ostreatus alters the hepatic metabolism of the PI, self-reported incidence of muscle aches, and measurement of liver and muscle enzymes. HMG CoA reductase inhibition activity after P. ostreatus ingestion will be measured.
Seven of the 20 patients have completed the trial to date with no safety issues observed. Th e goal is to fully enroll the study by the end of summer 2005. Effi cacy and safety data will be available at the time of presentation.
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Selenium Enrichment of Grifola frondosa (Dicks.:Fr.) S.F.Gray (Maitake) Mushrooms

Robert B. Beelman & Daniel J. Royse
Departments of Food Science and Plant Pathology, Th e Pennsylvania State University, USA Grifola frondosa (Dicks.:Fr.) S.F.Gray (Maitake) is a popular culinary mushroom that is well known to contain unique β-glucans, which have potent immune-modulating and antitumor properties. However, they generally contain low levels of important micronutrient minerals, such as selenium. Selenium has recently generated great interest in nutritional and medical research, because it serves as a cofactor for the enzyme glutathione peroxidase, which is involved in quenching free radicals. Th us, the objective of this study was to determine if G. frondosa can be enriched with selenium by addition of sodium selenite to the growth substance, as was done previously with Agaricus bisporus ( J.Lge) Imbach. Two separate crops were grown using a sawdust-based synthetic medium with various levels of selenium added by addition of appropriate amounts of sodium selenite prior to pasteurization and inoculation. Basidiomes were harvested from the treated substrates, weighed for yield determination, freeze-dried for solids determination, and than analyzed for selenium content using graphite-furnace atomic absorption spectrophotometry. Yield was not signifi cantly affected by addition of selenium to the substrate, but basidiomes were harvested 5-7 days earlier when selenium was added. No selenium (<0.5 µg/g) was detected in the untreated (control) substrate and the basidiomes harvested from it. Selenium increased in the basidiomes in direct response to levels added to the substrate. Treated substrates contained 0.6, 2.4, and 7.2 µg/g (d.w.) selenium and basidiomes harvested from them contained 0.6, 2.2, and 9.3 µg/g (d.w.), respectively. Th ese results indicate that G. frondosa can be predictably enriched with selenium in a manner similar to Agaricus bisporus to become an excellent nutritional source of selenium. Also, production of Maitake extracts or powders for nutraceutical or medicinal purpose that can contain signifi cant levels of selenium in addition to β-glucans would be possible.
Mushroom Poisoning in North America
Michael W. Beug
Th e Evergreen State College, 2700 Evergreen Parkway NW, Olympia, WA 98505, USA Americans remain a very mycophobic people, although in the last 30 years popular mushroom identifi cation fi eld guides, a journal for amateurs (Mushroom: Th e Journal ), and more than 64 mushroom clubs have led to a growing number of mushroom enthusiasts. In the Northwest, commercial mushroom picking has become economically important, with many pickers out gathering in the wild, sometimes with little or no knowledge of mushroom identifi cation or mushroom ecology. All of this occurs with relatively few cases of mushroom poisoning, although a parent fi nding a child with half a mushroom dangling from his mouth will inevitably lead to panic.
In order to assist doctors, who are often unfamiliar with mushroom poisoning, and to better inform the public, the North American Mycological Association (NAMA) maintains a continent-wide group of identifi ers who stand ready to assist doctors and poison centers in identifying mushrooms suspected of causing poisoning. NAMA provides educational materials on mushroom identifi cation and information on diagnosis and treatment of mushroom poisoning and promotes the reporting of mushroom poisoning and the treatment used.
Th e challenge we face is to get a more complete reporting of poisonous incidences in order to understand the frequency and severity of mushroom poisoning in North America. New patient confidentiality rules also inhibit reporting of poisonings, even though the reports do not involve identifying individuals involved.
What is clear is that the majority of cases reported to poison centers involve ingestion of mushrooms by children where there are no adverse symptoms. Cases involving symptoms typically involve gastro-intestinal distress. Th e distress is at times severe and may leave the individual in a weakened state for a week or more. Th e main threat of death from mushroom ingestion is from highly toxic species by young children and by individuals not otherwise in good health. Adults in good health normally survive ingestion of even the deadliest mushrooms provided they get prompt, good medical treatment and provided that they have not consumed a huge amount of the toxic species.
A major challenge in North America is to educate recent immigrants who may make mushrooms a signifi cant part of their diet and may pick toxic species that resemble edible species from their home country.
Th is presentation will focus on characteristics of mushrooms in North America that cause substantial numbers of poisoning, with an emphasis on cases in the past 4 years. Previous research from our laboratory has found mushrooms, including white button mushrooms, containing phytochemicals that can suppress aromatase/estrogen biosynthesis. Aromatase is the enzyme that converts androgen to estrogen. An abnormal expression of aromatase in breast tissue is considered to be a risk factor for breast cancer. In our laboratory, we have found that of the seven vegetable extracts tested, mushroom extract was the most eff ective in inhibiting the activity of human placental aromatase activity. Cell culture experiments were performed to further evaluate the anti-aromatase and anti-breast-cancer activity of mushrooms. Our laboratory has prepared one breast cancer cell line, MCF7aro. Th is cell line is ER positive/aromatase positive and demonstrates increased cell proliferation in the presence of testosterone. Th e addition of mushroom extract decreased the advantage gained by the addition of testosterone to a similar level as seen with 4-OHA, a known aromatase inhibitor. Furthermore, mushroom extract was found not to aff ect the proliferation of MCF-10A, a noncancer cell line. Th ese fi ndings suggest that the inhibitory eff ect of white button mushroom extract is through a specifi c anti-aromatase action, not a cytotoxic eff ect.
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To better understand the cancer protective eff ects of mushrooms, our laboratory decided to characterize the anti-aromatase chemicals and to investigate the in vivo action of mushroom extract. Th ree sets of animal experiments have been conducted, and the results suggest that the oral intake of mushroom extracts might slow down MCF-7aro-derived tumor growth in nude mice. Histological examination of the tumors revealed that the levels of apoptosis between tumors from the control and mushroomextract-fed animals were similar, once again indicating that the tumor-suppressing eff ect of mushroom extract is not through a cytotoxic eff ect. Th ese results signifi cantly indicate that these phytochemicals in mushroom are orally active and maintain their activity after ingestion. Preliminary studies from this laboratory have found more than one chemical in mushrooms that can inhibit aromatase, and some of them may be fatty acid derivatives. Th e exact nature of the active chemicals is not yet determined.
A series of in vitro and in vivo experiments have also been carried out to demonstrate that white button mushrooms can be a chemopreventing agent against prostate cancer. A 20% methanol extract of white button mushrooms has been found to contain phytochemicals that suppress steroid 5α-reductase and aromatase. Steroid 5α-reductase converts testosterone to dihydrotestosterone (DHT) and has been shown to play an important role in the development of prostate cancer and benign prostate hyperplasia. Th e use of steroid 5α-reductase inhibitors has been found to decrease the incidence of prostate cancer. Cell culture experiments involving cells treated with mushroom extract for 10 days have been carried out. Th rough these experiments, we have revealed that white button mushroom extract has the ability to suppress the growth of hormone-resistant prostate cancer cells such as PC-3 and DU145 as well as hormone-dependent LNCaP cells in a dose-dependent manner. Th e mushroom extract was found not to aff ect the proliferation of normal prostate epithelial cells.
We have also carried out in vivo chemoprevention studies using prostate cancer cell-implanted male athymic nude mouse models. Th ere were two groups of mice gavaged with two diff erent concentrations of mushroom extract and also a pair-fed control group that was gavaged with water. From this in vivo study, we demonstrated that our mushroom extract decreased tumor size in a dose-dependent manner. Th erefore, our fi ndings on white button mushrooms indicate that the intake of mushrooms could reduce the incidence of breast cancer and prostate cancer. An eff ective chemopreventive agent should not signifi cantly alter quality of life and is ideally inexpensive, safe, and well tolerated. Th is prevention method should be readily available and aff ordable to the general population, including underserved populations.
While it is exciting to fi nd that mushroom extract contains anti-aromatase and anti-5α-reductase chemicals, it is reasonable to think that mushroom chemicals also aff ect other cellular pathways. As the fi rst step, we have performed gene expression microarray analysis on MCF-7aro tumors from the mushroom-fed animals and those from the control animals. It was our goal to identify additional gene targets whose expression could also be modulated by the mushroom diet. We have performed the analysis using Aff ymetrix Human Genome U133A among three biological replicates-i.e., RNAs were isolated tumors from three individual animals and analyzed separately. Th e intensities of the probe signals on GeneChips were statistically normalized following a background noise subtraction and were analyzed using algorithms in R/Bioconductor. We compared more than 22,000 gene expressions using twosample t tests and applied the Benjamini-Yekutieli p-value correction to control the false discovery rate. Using a minimum fold change criteria of 1.2 and an adjusted p-value cutoff of 0.05, we identifi ed 515 genes that were upregulated and 1805 genes that were downregulated in tumors from mushroomfed mice versus those from control mice. Th e results indicate that a higher percentage of signal transduction genes are upregulated, and a higher percentage of genes involved in DNA processing and transcription/translation are downregulated in tumors from mushroom-fed mice versus those from control mice. A careful evaluation of the results from microarray analysis will yield novel insights into the mechanisms as well as important signal-transduction pathways regulated by the phytochemicals in white button mushrooms.
Recently, we extended our studies on other medicinal mushrooms. Lignocellulose composes more than 60% of plant biomass produced on earth. In addition, municipal and agro-industrial waste generation is fast increasing and causing pollution and many other environmental problems. Th e agro-industrial waste is a potentially vast source of energy, substrate for mushroom productions, biofertilizers, animal feed, enzymes, and other biochemical products. Th e most effi cient decomposers of lignocellulose are the white-rot fungi because of the capability of these fungi to synthesize the relevant hydrolytic (cellulases and hemicellulases) and oxidative (ligninolytic) extracellular enzymes required to degrade the major components of the substrate-i.e., cellulose, hemicellulose, and lignin-into low-molecular-weight compounds that can be assimilated in fungi nutrition.
Recently, extensive research on these fungi has been conducted with the aim of isolating new organisms with tremendous secretion of ligninolytic enzymes as well as enzymes with properties important for their industrial application in the bioremediation of polluted, hazardous xenobiotic soils and industrial waters; biobleaching and biopulping; the textile, dye, and food industries; biotransformation of pharmaceutical and other intermediates; biosensor construction; cosmetics; medicine; analytic biochemistry. All these biotechnological applications require huge amounts of enzymes. However, their application is hindered because the enzymes that are presently being investigated are still expensive because of the low yield and high cost in production and isolation. Overexpression of laccase and peroxidases in heterologous systems has not been achieved yet, and they still have to be obtained from natural sources. Th erefore, the search for powerful producers of enzymes and the development of alternative technologies for enzyme production are mandatory. Consequently, an overview of various approaches will be presented aiming to stimulate the production and yield of target enzymes as well as the analysis of the studies proving that the regulation of lignocellulolytic enzymes synthesis appears to be subject to the complex eff ects of nutritional, environmental, temporal, and genetic factors. Understanding of physiological mechanisms regulating enzyme synthesis in lignocellulose bioconversion could be useful for improving the technological process of edible and medicinal mushroom production.
Special attention will be paid to edible and medicinal mushrooms of the genus Pleurotus and Lentinus edodes (Berk.) Singer, which serve as the basis for various biotechnological and environmental applications. Some of these applications are traditional and are practiced throughout the world, and some need further research and development. Cumulative evidence indicates that the selection of an appropriate cultivation technique and plant residue adequate for fungus growth and target enzyme synthesis plays an important role in the development of an effi cient biotechnology. Cultivation of Pleurotus strains and L. edodes on wheat straw, tree leaves, and cotton wastes as growth substrates showed clear physiological and biochemical changes taking place during plant raw material colonization and fructifi cation. Th e vegetative growth of these edible mushrooms is characterized by the comparatively low activity of polysaccharases and high activity of ligninolytic enzymes. During the period of fruiting body formation, when mushroom growth demands a large quantity of plastic materials and energy, the secretion of cellulases and xylanase sharply increases to accelerate polysaccharide hydrolysis. In contrast, ligninolytic enzyme production appears to be, to some extent, repressed in preventing the expenses of constructive materials and energy.
In addition, the investigation of the hydrolytic and oxidative enzyme production during Pleurotus spp. and L. edodes cultivation is mandatory, because after harvesting the fruit bodies the residual spent substrate may become a cheap source of lignocellulolytic enzymes for several biotechnological applications, and it may be used as a bioremediation agent.
Scientifi c names in use for edible and medicinal mushrooms can change as a result of new research on relationships and species limits, issues relating to the international rules controlling the publication of scientifi c names, or even incorrect identifi cations. Sadly, not all mycologists explore or utilize all the options now available under the internationally agreed rules (Th e International Code of Botanical Nomenclature) to avoid making name changes before publishing them. Progress in the development of the rules to these ends is considered in the light of actions and discussions at the International Botanical Congress in Vienna in July 2005. Issues of changing names are a problem across the whole of biology, and various ways of limiting changes have been proposed and debated-for example, by establishing protected lists of names and requiring the registration of newly published names. Mycologists have also recently launched MycoBank, a freely available database containing descriptions and illustrations and assigning each species of fungus a unique reference number (to be allocated before hard-copy). Initiatives are being taken by the Global Biodiversity Information Facilty (GBIF), a body established by the Convention on Biological Diversity, to develop and support schemes to improve, harmonize, and simplify approaches to scientifi c names across all groups of organisms. Th e International Society for Mushroom Science (ISMS) and the International Commission on the Taxonomy of Fungi (ICTF), as well as regional and national mycological societies, should be involved in and contribute to the important debates and actions now underway or being planned. Nevertheless, much will always depend on the integrity, responsibility, and actions of individual mycologists. Trametes versicolor, formerly Coriolus versicolor, is a common fan-shaped polypore fungus of dead and dying trees throughout the world, which is an important part of forest ecology as a primary decomposer of hardwood. Th e fungus is characterized among the white-rot basidiomycetes. T. versicolor produces a laccase used to detoxify xenobiotics such as polychlorinated biphenyls, dyes, and a variety of synthetic polymers and as a pulp biobleach for making paper.
Turkey tail is arguably the best-researched medicinal mushroom, with a number of controlled clinical trials demonstrating increased long-term survivability in patients with gastrointestinal cancers, and to a lesser degree other cancers, with oral application of concentrated extracts of the fruit bodies and mycelium, particularly PSK and PSP. Th ese commercially produced extracts are often prescribed along with chemotherapy for treating cancer in Japan and are paid for by national health care.
PSK and PSP have demonstrated a wide range of immunological eff ects in vitro and in vivo, particularly reticuloendothelial system activation, cytokine modulation (IFN-γ production, IL-2 production), enhancement of dendritic cell viability, T-cell maturation, natural killer cell activity, antibody production, and antitumor and anticancer eff ects. Th e extracts can inhibit carcinogenesis and tumor cell growth by activating cancer cell apoptosis.
Current clinical use in North America, Europe, and Asia of products containing turkey tail extracts and their use as health food supplements has rapidly increased in the last few years, with many types of products becoming available. Th ey are often recommended as supportive treatment for their supposed immunorestorative eff ects in patients with chronic conditions such as various cancers and viral syndromes such as hepatitis C and for its hepatoprotective eff ects.
Since 1990, a number of controlled clinical trials have been performed in Japan with PSK as a supportive treatment in hospitals and clinics for treating patients with a variety of cancers, particularly colorectal and stomach cancer, but also breast and lung cancers. PSK is given orally, always along with various chemotherapeutic regimes. In several of these multicentric trials (n = 103-462), the 15-year survival rate was increased by 10-15%, and side eff ects of chemotherapy, such as nausea and anorexia, were reduced when PSK was given along with chemotherapy. Improvements in immune functions such as blood leukocyte and neutrophil counts, serum IgG and IgM, and body-mass index were seen in patients receiving turkey tail extracts with chemotherapy vs. chemotherapy alone.
Fundamental questions about the eff ectiveness of turkey tail extracts for life prolongation and mitigation of side eff ects from chemo-and radiotherapy in cancer patients, as well as its eff ectiveness as an immunorestorative and antiviral treatment in patients with chronic viral syndromes, remain to be fully answered. Th e dose, the solvents used for extraction, the source of starting material, the question of whether fruiting bodies or more easily obtained mycelium cultures should be used, and the duration of treatment have only been partially clarifi ed. Because ubiquitous cell wall components of fungi (including yeasts) and bacteria, (1→3)-β-d-glucans, are thought to be among the most important active constituents, a careful review of the large body of existing literature on the cellular mechanisms of eff ects on the immune system with oral exposure of these compounds has to be carefully considered.
Cancer Risk Reduction by Intake of Mushrooms and Clinical Studies on EEM
Tetsuro Ikekawa
Japanese Association for Integrative Medicine ( JAIM), Sanshin Bldg. 2-15-14, Uchikanda, Chiyoda-ku, Tokyo 101-0047, Japan
An epidemiological survey was carried out concerning farmers producing Flammulina velutipes (W.Curt.:Fr.) Singer "Enokitake" from 1972 to 1986 in Nagano prefecture, Japan. Cancer death rates of the farmers were lower than those of the average rate of total Nagano prefecture. Intake of edible mushrooms was suggested as being eff ective for risk reduction of cancer.
Th is was an ecological study. Next, a case-control study was made to elucidate the relationship between risk reduction of cancer and intake of edible mushrooms on stomach cancer in the same prefecture from 1998 to 2002. Th e odds ratio (OR) of subjects who were practically not ingesting mushrooms at all was 1.00; the OR of those ingesting Hypsizygus marmoreus (Peck) H.E.Bigelow (Bunashimeji) or Pholiota nameko (T.Ito) S.Ito et S.Imai (Nameko) more than once a week was 0.57 and 0.56, respectively. Whereas the OR of subjects taking mushrooms less than once a week was 1.00, the OR of those taking Flammulina velutipes more than three times a week was 0.66, and the OR of those taking Lentinus edodes (Berk.) Singer "Shiitake" more than three times a week was 0.95. It can be concluded that the intake of Hypsizygus marmoreus, Flammulina velutipes, and Pholiota nameko has the possibility of decreasing stomach cancer incidence.
Studies on antitumor activities of mushrooms were carried out in the National Cancer Center, Japan. Many antitumor polysaccharides and protein-bounded polysaccharides were isolated from mushrooms.
Based on these studies, extracts were made from Hypsizygus marmoreus and Flammulina velutipes, and a preparation called "EEM" (extracts of edible mushrooms) was supplied. Clinical studies of EEM were performed to investigate the eff ectiveness for cancer patients. Positive eff ects of EEM were studied on the cachexia of advanced cancer patients in comparison with MPA (methylacetoxyprogestrone). EEM revealed better results than MPA in clinical response, performance status (PS), and quality of life (QOL). Another clinical study was made with a combination therapy of EEM and cancer chemotherapy agents for advanced cancer patients. Th e clinical response rate, PS, and QOL of the patients treated with combination therapy (EEM and anticancer drugs) were better than those of the patients treated with anticancer drugs alone. Th e positive eff ects of EEM were also investigated for a precancerous lesion on the esophageal mucosa. After the patients of grade II of atypical hyperplasia on the esophageal mucosa were administered EEM tablets for 6 months, a positive eff ect of EEM was found.
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Protecting Intellectual Property Assets of Mushroom Genetic Resources for Invention and Innovation
Shung-Chang Jong
American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, USA; sjong@atcc.org Th e concept of intellectual property (IP) allows people to own creativity and innovations in the same way as physical property. An IP asset is any codifi ed knowledge, innovation, or practice of actual or potential economic value, associated with fundamental research, analysis, and manipulation of biological systems, biological prospecting, industrial applications, or commercial use. Mushroom genetic resources are currently being utilized and exploited by the pharmaceutical, cosmetic, agricultural, food, enzyme, chemical, and waste-treatment industries. Nevertheless, the role of IP assets in today's knowledge-driven enterprises is frequently overlooked, despite their potential as sources of both monetary value and fi nancial gain. IP rights are often under-managed or under-leveraged. Th e challenge is how to create, protect, and extract value from IP assets for invention and innovation.
In the valuation of IP assets, it is important to diff erentiate between "invention" and "innovation." Because an invention may not involve the commercialization of new ideas, it is obvious that not all inventions result in innovation. Innovation is an interactive process of eff ectively creating, managing, and leveraging an invention and successfully bringing new products to market. Th erefore, IP assets can be used eff ectively to sustain mushroom production and business development.
Th e IP assets of mushroom genetic resources are divided into three basic yet interdependent components: (1) intellectual material, (2) intellectual capital, and (3) intellectual property. Intellectual material provides both tacit and codifi ed knowledge of mushroom genetic materials including intangible content (genetic information), implemented know-how (product/process innovation), and knowledge databases (bioinformatics). Intellectual capital en com passes various kinds of knowledge and innovative ideas that are mainly driven by, and derived from, individuals or groups of scientists and technologists. Intellectual assets with legal protection become intellectual property. An IP right is thus a legal right granted or registered under the relevant national or regional law by the relevant IP offi ce. Codifi ed knowledge and know-how form a body of interactive IP assets that relates directly to product/process innovations and codifi ed ideas of their creators and users.
It is often not possible to protect IP assets and gain IP rights unless they have been applied for and granted or registered through an IP system. IP assets that can be protected by formal legislation are patents, trademarks, copyrights, and plant breeders' rights. Know-how and trade secrets are forms of IP that are not protected by formal legislation but have national and international value. As with any property, IP assets possess specifi c dollar value and can be bought and sold.
One of the methods of gaining the value of mushroom genetic resources through IP is with a material transfer agreement (MTA). An MTA is a contract generally utilized when any proprietary material and/or information is exchanged with "trade secret" protection as embodied, for example, in various state laws in the United States. It defi nes the rights of the provider and the recipient with respect to the mushroom materials and any replicates or derivatives. A replicate is any mushroom material that represents a substantially unmodifi ed copy of the original material and includes material produced by the growth of cells or amplifi cation of material. A derivative is material created from the original material that is substantially modifi ed to have new properties. Derivatives include recombinant DNA clones made using a vector. However, know-how and trade secrets are, in certain cases, protected contractually by the application of certain legal concepts and statutes, such as customary laws and practices. Signed contracts such as MTAs are the most powerful tools in trade secret and customary laws in which registration is not required.
Today, the new challenge for mushroom scientists and technologists is to realize that IP should no longer be considered as an inert legal title, but as an economical asset that can realize the potential of knowledge and creativity. PI assets are tools that maximize the value of special knowledge, either by providing data or information or by delivering expertise and augmentation to mushroom scientists and technologists. Concerns about access to the IP assets of mushroom genetic materials have recently surfaced because of the reluctance of IP owners to allow their use for research that may lead to commercial applications. IP holders need assurance that access will be controlled. A number of bilateral and multilateral initiatives have been implemented to protect IP assets among the proposed users. All agreements are negotiated in a manner that is coherent and mutually supportive of national and international laws, local customs, rules, and regulations and implemented through collaborative action by governments, appropriate organizations and professional societies, fi eld collectors and their sponsors, and curators and users of mushroom genetic resources.
Although the Convention on Biological Diversity (CBD) establishes principles of access to, and benefi t sharing of, biological materials, it does not establish any specifi c mechanisms for such activities. Several factors infl uence the design of mechanisms for access and benefi t sharing. Two are of particular importance: (1) how clearly the target for access and sharing can be defi ned, and (2) whether the transaction costs associated with more precise targeting outweigh the benefi ts to be shared. At the same time, expectations of contingent returns must be tempered by the real probabilities of discovery of new applications. Diff erent contractual arrangements have been designed for diff erent resources and diff erent uses. Negotiation of legal and policy tools for formulating and obtaining mutually agreed terms following prior informed consent can include many of the following: (1) access agreement, (2) confi dentiality agreement, (3) material transfer agreement, (4) research agreement, (5) intellectual property protection agreement, (6) co-development agreement, (7) technology licensing agreement, (8) distributorship agreement, (9) commercial agreement, and (10) benefi t-sharing agreement.
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Methicillin-resistant Staphylococcus aureus (MRSA) is currently one of the most prevalent pathogens in nosocomial infections. Because hospital-acquired MRSA strains exhibit resistance to many antibiotics and are transmitted from patient to patient via transiently colonized hands of hospital personnel, MRSA infections pose a serious problem for hospitalized patients.
We found that extracts of the fruiting bodies and the mycelia of Hericium erinaceus (Bull.:Fr.) Pers. exhibited anti-MRSA activity. Th erefore, we tried to isolate the anti-MRSA compounds from the fungus.
Isolation of the active compounds was guided by anti-MRSA activity. Th e fungus was cultivated by shaking at 30 °C for 4 weeks. Th e culture was centrifuged, and the resulting residue was extracted with 85% ethanol, and the extract, after evaporating the solvent, was partitioned between chloroform and water and then ethyl acetate and water. Repeated silica gel chromatography and HPLC of the chloroform-soluble and ethyl-acetate-soluble parts gave fi ve active compounds. Th e fruiting bodies of the fungus were also extracted with 85% ethanol, and the extract was concentrated and fractionated by solvent partitions between chloroform and water, and then ethyl acetate and water. Repeated silica gel chromatography and HPLC of the chloroformsoluble part gave an anti-MRSA compound.
As a result, erinacines A (1) and B (2) were isolated as anti-MRSA compounds from the mycelia (Fıgure 1). Th ese compounds have already been isolated as nerve growth factor (NGF) stimulators (Kawagishi et al., 1994 (Kawagishi et al., , 1996 . Determination of the structures and estimation of detailed biological activity of the other active compounds are now in progress.
In addition, a clinical test of this mushroom was done in a hospital in Japan, and MRSA in some patients disappeared when they were given this mushroom to eat. Th e hepatoprotective eff ects of functional rice, produced by cultured Agrocybe cylindracea (Agaricomycetideae) on waxy brown rice, were investigated. After oral administration of the methanol extracts of functional rices for 14 days, rats were treated with carbon tetrachloride to induce hepatotoxicity. Th e enzyme activities were determined, and biochemical analyses of serum were carried out in order to examine the hepatoprotective eff ects exerted by the samples. A histological study on liver tissue using electron microsope was also conducted. Th e body weights and internal organs weights of the rats were measured. Th e body weight of the group treated with only CCl₄ increased less than those of the groups fed with sample extracts prior to CCl₄ treatments. Th e weight of internal organs among the treatment groups did not show substantial diff erence except that the hepatic hypertrophy was observed in the group treated only with CCl₄. On the other hand, the COCIII group and the CIC groups administered with the methanol extracts from the waxy brown rice and cultured with A. cylindracea, respectively, showed an organ weight similar to that of the normal group.
Th e activity of serums AST and ALT of rats increased highly in the group treated with CCl₄ only. Th e COC and CIC groups showed a strong suppression on the AST and ALT augmentation almost to the level of normal rats without CCl₄ treatment. In particular, the CICII and CICIII groups were able to maintain both the AST and ALT activity in a manner similar to the normal group without CCl₄ treatment, and was statistically not signifi cant.
Th e activity of serums ALP, LDH, and Υ-GPT was signifi cantly increased by carbon tetracholoride treatment, but methanol extracts of brown rice, cultured with A. cylindracea, signifi cantly decreased the activity of those emzymes, which was supposed to be increased by the carbon tetrachloride treatment. CICII and CICIII groups especially demonstrated a strong protective eff ect by suppressing the increase of these enzymes.
Th e control group treated only with CCl₄ showed a severe decrease in albumin level, total protein, and HDL-cholesterol content in comparison with the normal group. Th e COC group and the CIC group considerably alleviated the decrease of those components. Th e content of total cholesterol, triglyceride in liver was increased by administration of CCl₄. However, the COC and CIC groups did not show the increases and kept them at almost the same level as the normal rats without CCl₄ treatment.
Th e content of lipid peroxide in the CCl₄-treated group signifi cantly increased in comparison with the normal group, but the COCIII and CIC groups had a tendency to maintain lipid peroxide content at a much lower level.
Th e liver tissue of rats was observed by transmission electron microscope. Th e injury range of cells was shown to be widest in the control group treated with CCl₄ only. In groups administered with the extracts from waxy brown rice cultured with Coprinus Hepatoprotective Effects of Waxy Brown Rice Cultured with Agrocybe cylindracea (DC.) Gillet comatus (Müll.:Fr.) S.F.Gray and C. cinereus (Schaeff .: Fr.) S.F.Gray prior to CCl₄ treatment, diminished lipid degeneration and infi ltration of local infl ammation caused by CCl₄ were alleviated considerably. In particular, the CICIII group showed almost the same integrity as normal rats without CCl₄ treatment.
Medicinal mushrooms possess a variety of health promoting qualities as well as being a potential source of a variety of pharmaceuticals for some diseases, including cancer. Although most of the attention for their anticancer activity revolved around the activity of high-molecular-weight polysaccharides with no clear mechanism of action, our focus is on low-molecular-weight mushroom substances with a well-defi ned mechanism of action.
A neoplasm is an abnormal mass or colony of cells produced by a relatively autonomous new growth of tissue arising from the clonal expansion of a single cell that has undergone neoplastic transformation, which is usually accompanied by the loss of some specialized functions and the acquisition of new biological properties mediated by alteration in the expression or function of specifi c molecular targets. Our research interest is on mushroom substances that specifi cally modulate molecular targets implicated in carcinogenesis, especially in chronic myelogenous luekemia (CML) and prostate cancer (PCa).
CML is a malignancy of pluripotent hematopoietic cells characterized by distinctive cytogenetic abnormality resulting in the creation of a p210 Bcr-Abl fusion protein with increased tyrosine kinase activity.
Imatinib is a potent inhibitor of Bcr-Abl and is used as standard therapy for CML. Unfortunately, clinical effi cacy continuously decreases with the advancement of the disease. Secondary resistance is mostly due to the acquisition of point mutations in Bcr-Abl, which argues for the need of developing alternative inhibitors of Bcr-Abl.
Medicinal mushrooms exhibiting selective anti-CML activity were selected. Active mushroom substances induced apoptosis and erythroid diff erentiation in CML cells and caused a reduction in Bcr-Abl levels. Focusing on mushroom #540 and #514, we show that medicinal mushroom substances were eff ective in inhibiting auto-phosphorylation from wild types as well as from imatinib-resistance mutants of Bcr-Abl.
PCa is the second leading cause of death in Western men. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops into hormone-refractory tumors due to the accumulation of mutations in the androgen receptor (AR) or to the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of PCa in androgen-independent mechanisms.
Whereas PCa is very common in Western countries, its levels are very low in several countries in Asia. Several reports linked Eastern diets and cancer occurrence, especially for PCa. Of special interest is the implication of several mushrooms in the prevention of PCa in Asia.
We evaluate the ability of mushroom substances extracted from our collection of mushroom strains to interfere selectively with the activity of AR, the leading molecular target implicated in the development and maintenance of hormone-refractory PCa. Data showing anti-prostate cancer activity and the ability to modulate AR and other molecular targets will be presented. Ganoderma is a very distinctive genus of whiterot polypore fungi that is primarily characterized by the formation of a double-walled, generally echinulate basidiospore. Most Ganoderma species are very variable macromorphologically and lack micromorphological distinctiveness. As a consequence, earlier taxonomic studies in the genus have created many synonymous names and have resulted in largely ambiguous species delimitation and identifi cation systems, making species identifi cation in the genus virtually impossible. Ganoderma strains used in oriental folk medicine refer to Reishi and have traditionally been labeled Ganoderma lucidum (W.Curt.: Fr.) P. Karst. in the scientifi c literature. However, there is now accumulative evidence that most species reported as G. lucidum in most of the pharmacological and phytopathological studies were wrongly identifi ed.
Medicinal Mushroom Substances as Cancer
G. lucidum was fi rst described as Boletus lucidus by William Curtis in 1781 from a fi lbert plant (= Corylus avellana) in London, UK. Curtis's original collection (i.e., the type specimen) has been lost. Th e actual type is represented in a color plate, which is in agreement with the International Code of Botanical Nomenclature. However, the typifi ed plate is of no use for providing cultural characteristics and genetic information that would be useful for distinguishing G. lucidum from the other British laccate Ganoderma.
Over the years, at least 166 laccate Ganoderma species have been described worldwide, of which at least 48 names were, at some point, considered to be synonyms of others. Th ere is nevertheless a strong consensus about the true identity of G. lucidum among contemporary European mycologists. Molecular phylogenetic studies indicate that Ganoderma is a young genus in agreement with earlier morphological evidence as pointed out by the Norwegian mycologist Leif Ryvarden. DNA studies have shown that the G. lucidum species complex is composed of several species that can be diffi cult to distinguish from one another. Th ese species include the European G. valesiacum Boud.; G. ahamdii Stey., described from Pakistan; North American G. tsugae Murrill and G.oregonense Murrill; and other taxa variously labeled G. resinaceum Boud., G. oerstedii Fr., and G. praelongum Murrill.
Recent genetic and biogeographic studies have indicated that most Ganoderma species are geographically restricted. G. lucidum is probably restricted to western parts of Europe, although its distribution range can possibly also include parts of Siberia and of north western regions of China. Based on molecular phylogenetic evidence, it appears that most collections labeled G. lucidum in North America do in fact best correspond to the taxon labeled G. resinaceum in Europe, whereas G. tsugae in North America is genetically very close to the "true" G. lucidum from Europe.
Th is leads to the question of what is the Oriental Reishi? A nonexhaustive molecular survey of taxa labeled G. lucidum in Asia, including strains com-
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Incorrect taxonomic identifi cation of Ganoderma strains hampers comprehensive strategies for drug discovery as well as for monitoring and managing diseases caused by Ganoderma in woody crops and forest ecosystems. Both molecular phylogenies and morphological evidence indicate that Africa probably harbors the highest genetic and taxonomic diversity in the genus.
Numerous species of medicinal fungi evolved in forests, and humanity has long harvested these fungi from their native arboreal habitats. Many of these species are now being cultivated; however, some are still harvested from forests. For instance, nutraceutical ectomycorrhizal mushrooms are diffi cult to cultivate. Inonotus obliquus (Ach. ex Pers.) Pilát (Chaga) does not produce the betulin-containing sclerotia known as chaga without infecting live birch trees, and among customers that value natural products, wild-harvested Ganoderma species can command premium prices. Lastly, cultivated species can be improved by isolating new cultivars from wild strains to replace senescing mycelia, to obtain strains that have better medicinal properties, or to select clones with superior growth characteristics in cultivation.
Scientists and foresters have a broad appreciation of the innumerable functional roles that fungi play in sustaining healthy, productive, resilient, and diverse forest ecosystems, but quantifying the value of these functions is often diffi cult because the roles that fungi play are so fundamental and all-encompassing that forests would not even exist without fungi. Focusing more specifi cally on the monetary value of medicinal fungal species in forests is also diffi cult because such fungi are expensive and time-consuming to study in situ, the products that humans derive from fungi are often harvested sporadically or opportunistically, and much potentially useful information is proprietary. Fungi are too often overlooked in forest management plans because their value is harder to quantify than amenities such as trees or water and because some foresters have a cultural bias that fungi are unimportant.
Th e goal of this study is to examine how the value of selected forest fungi might be quantifi ed so that foresters can better justify management plans that sustain their wild populations in forested ecosystems.
We begin by examining the relative value of several edible forest fungi and timber in scenarios in which forests are managed for the production of both. Assumptions about how to compare these annually (mushrooms) and periodically (timber) harvested forest products are made and explained, along with Next, we discuss how the assumptions of these comparisons might diff er for medicinal fungi that are harvested from forests, rather than cultivated. Diff erences include mode of nutrition, distribution and abundance on the landscape, periods between sporocarp harvest, inoculation methods, and forest management goals. Examples will include chaga harvesting in boreal birch forests and Ganoderma spp. harvesting in the temperate rain forests of western North America.
Valuing Medicinal Fungi in Forest Management
We conclude by considering the value of genetic diversity among and within wild populations of medicinal fungi. Advances in pharmacology, fungal biotechnology, genetic analyses, and genetic manipulation might ameliorate some of the need for genetic diversity in wild populations, but these technologies could still pose unknown perils to human or ecosystem health.
Regardless of the actual risks, the public is likely to remain fearful of genetically modifi ed fungi, as evidenced by substantial markets for organically grown mushrooms and derivative products. We explore similar eff orts to quantify the value of genetic diversity in other biotic resources and how these approaches could apply to populations of medicinal fungi in forests. Such information will likely improve the ability of foresters and policy makers to ensure the fungal populations are adequately considered in forest management plans and that this resource remains available to the medicinal mushroom industry.
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Many mushrooms are reported to have antiviral activity against viruses that cause human disease. Th e active substances described include polysaccharides, conjugated polysaccharides, proteins, peptides, lignins, triterpenes, phenoloic derivates, and nucleic acid bases. RC 28 is an antiviral protein of MW 28 kD prepared from aqueous extracts of the mushroom Rozites caperata with novel antiviral activity. It is active exclusively against enveloped viruses including human Herpes viruses HSV-1 and HSV-2, Cytomegalovirus, Varicella zoster, Respiratory syncytial virus, and Infl uenza Virus type A. It is not active against the non-enveloped viruses Adenovirus type 6, Coxsackie viruses B5 and B6, and several strains of ECHO viruses. Our present objectives are to obtain the complete amino acid sequence of RC 28, determine its antiviral mechanism, and identify its cellular targets. I will present some initial studies with these objectives in mind.
Th e antiviral eff ects of RC 28 were studied in Buff alo Green Monkey kidney cells (BGMK) and Hep-2 cells infected with the KOS strain of HSV-1 virus. Th e synthesis of viral proteins in BGMK cells was studied using Western blots of infected cell extracts from 4-12% PAGE gels stained with antibodies to HSV-1. Eff ects of RC 28 on the early functions of the HSV-1 immediate early protein, ICPO, and disaggregation of PML nuclear bodies was studied in Hep-2 cells stained with anti-ICPO antibodies and anti-PML antibodies. Localization and colocalization studies of RC 28 with cellular organelles were studied in Hep-2 cells stained with antibodies to RC 28, lysosomes, proteasomes, and ICPO. Cellular targets were studied using the Invitrogen Yeast ProtoArray Slide Kit.
RC 28 interfered with the synthesis of viral structural proteins even when the drug was added as late as 13 hours after infection. RC 28 prevented the translocation of the HSV-1 immediate early protein, ICPO from the nucleus to the cytoplasm, and ICPO directed disaggregation of PML nuclear bodies. RC 28 localized exclusively in the cytoplasm but not in the nucleus of Hep-2 cells, and RC 28 did not colocalize with nuclear ICPO, cytoplasmic proteasomes, or lysosomes.
Presently, the drugs of choice for the treatment of Herpes virus infections are those that interfere with viral DNA replication-i.e., Acyclovir and second generation derivatives. RC 28 has unique and novel antiviral activities because it interferes with both early and late viral functions. It interferes with the functional activities of the immediate early protein ICPO and prevents the synthesis of late structural proteins even when RC 28 is added after viral DNA replication. Because of its unique antiviral activity, RC 28 may prevent infection by HSV-1 and HSV-2 Herpes viruses if the drug is applied within the fi rst few hours following contact. It is to be hoped that the elucidation of the antiviral mechanism of RC 28 and the identifi cation of its cellular targets will lead to the discovery of second generation RC 28-like drugs with even greater eff ectiveness, specifi city, and usefulness for the treatment of Herpes virus infections. Th e discovery of a Neolithic corpse in 1991 in an Alpine glacial fi eld, near the Austrian-Italian border, attracted worldwide attention. Th e fi nding's circumstances and the recovery of the mummy proved to be quite chaotic: it took fi ve days for the corpse and most of the artifacts found with it to be transferred to a lab of forensic medicine in Innsbruck, the capital of Tyrol. During this time (September 19-24, 1991) the Neolithic origin of the corpse was unknown, and at least 22 diff erent persons came into contact with it (Egg and Spindler, 1993) . Many of the artifacts, some damaged by the visitors, were carelessly thrown into a garbage bag and brought to Vent, the next mountain village. Th erefore, the exact original position of these artefacts (including fungal objects) could not be reconstructed.
Today, we know that the real age of the so-called "Ice Man" ranges, according to nine independent radiocarbon measurements, between 3350 and 3100 BC (Prinoth-Fornwagner and Niklaus, 1995) . Among the numerous items of the Ice Man's equipment were three fungal objects: two diff erent shaped, polypore-like fungal fragments, each mounted separately on a leather thong; and a mysterious "black matter," fi lling up the major part of his "girdle bag." Th e black matter, which was fi rst thought to be resin representing part of a prehistoric repair kit (Lippert and Spindler 1991; Egg and Spindler 1993) , was later shown to be tinder material prepared from the true tinder bracket Fomes fomentarius (L.: Fr.) Fr. (Sauter and Stachelberger 1992; Peintner et al., 1998) . Th e two whitish, polypore-like objects-one shaped more or less like a Scots pine cone, the other more spheroidal-were identifi ed as fruitbody fragments of the polypore Piptoporus betulinus (Bull.: Fr.) P.Karst. (Pöder et al., 1992; Peintner et al., 1998) .
So far, this represents the only case in which mushrooms were obviously part of a prehistoric person's equipment; it fi red the imagination not only of the public and the media but also of scientists. Due to a general fever of excitement, facts have often been mixed up with fi ctions.
Th us, for instance, our fi rst publication on the identity of one of the polypore-like fragments (Pöder et al., 1992) has prompted a fl urry of controversial discussions both in newspapers and scientifi c journals (e.g., Nieszery, 1992; Chapela and Lizon, 1993; Denman, 1993; Grant, 1993) . Our "educated guess" was-and still is-that the "razor strop fungus" (P. betulinus) does not provide a good tinder, and, therefore, might have served some purpose other than making fi re. Referring to biologically active compounds produced by P. betulinus and its special host-it grows exclusively on birch, which is regarded as the tree of life and fertility in many European and Siberian myths (e.g., Heeger, 1936; Wasson, 1968) -we indicated a possible medical-spiritual use. At this time (the existence of tinder material in the Ice Man's girdle bag was still unknown) the reaction of the public, archaeologists, and some biologists to our assumption was clearly negative. Mycological facts and ethnomycological hints could not argue archaeologists out of their The Ice Man's Fungi: Facts and Mysteries
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Such discussions stopped after the discovery of classic tinder material prepared from the tinder bracket Fomes fomentarius, which fi lled up the major part of the Ice Man's girdle bag (Pöder, 1993 . Others, obviously confusing "spiritual" with "spirituous," complained that the Ice Man was not a drug dealer. Referring to biologically active components produced by polypores, some authors (e.g., Sauter and Stachelberger, 1992; Capasso, 1998) mistook Piptoporus betulinus for Laricifomes offi cinalis. Th e latter contains agaric acid (2-hydroxynonadecan-tricarbonic acid) and has been used as a purgative or as medicine against pulmonary diseases right up to the 20t century. Th is mushroom was already known to the ancient Greeks for its medical properties and played an important spiritual as well as medical role in many societies worldwide (Buller, 1914; Blanchette et al., 1992; Blanchette, 1997; Peintner and Pöder, 2000) .
Th us, presumptions such as "the Ice Man was aware of his intestinal parasites and fought them with measured doses of Piptoporus betulinus," which contains agaricine (Capasso, 1998 ) is simply wrong (Pöder and Peintner, 1999) . In our studies, agaricine was not detected in the two fungal fruit body fragments of the Ice Man or in recent material of P. betulinus (Pöder et al., 1992; Pöder, 1993) . Th e pharmacologically active substances of P. betulinus are ergosta-7,22-dien-3-β-ol, fungisterol, ergosterol, tumulosic acid, and a group of triterpenes. Among the latter, polyporenic acid A, B, and C were separated (Cross et al., 1940) . Recently, the fi nding of a new antibiotic produced by Piptoporus betulinus, called piptamine (a tertiary amine) was published by Schlegel et al. (2000) . It is active against a series of Gram-positive bacteria and fungi including yeasts. Unfortunately, piptamin is a homonym of an alkaloid isolated from plants (Piptanthus nanus, Ormosia nobilis; Fabaceae) more than 40 years ago (Wilson, 1965) .
Although no indications could be found regarding a prehistorical use of P. betulinus, what can be fi nally said about the signifi cance of the Ice Man's fungi?
Concerning the Black Matter, its interpretation as classical fi re-starting tinder seems well confi rmed by the current body of evidence. Regarding the P. betulinus objects, it is much more diffi cult to fi nd an adequate answer without leaving a fi rm scientifi c footing. As outlined in detail by Peintner and Pöder (2000) , a merely alimentary use or use as some kind of commodity can be excluded; also a pure ornamentative or decorative function without any spiritual background seems very unlikely. Consequently, we have to admit that we simply do not know the Ice Man's intentions concerning these mushrooms.
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Mycoremediation (also called fungal treatment or fungal-based technology) is the application of fungi in remediation of polluted soils and aqueous effl uents. Th e fungi mostly used are wood-rot Basidiomycetes capable of degrading lignin (ligninolytic fungi). Most of these fungi cause white rot of wood, and so they are often called white-rot fungi (WRF). Th e ability of WRF to degrade lignin is due to a complex of extracellular enzymes-namely, lignin peroxidase, manganese dependent peroxidase, hydrogen peroxide generating oxidases, and phenol oxidases such as laccase. Th e lignin peroxidases were fi rst discovered in the basidiomycete Phanerochaete chrysosporium Burds., and in the 1980s this fungus was the main experimental model in lignin degradation research. Due to the nonspecifi c character of radical-mediated reactions of ligninolytic enzymes, the degradation of a wide variety of xenobiotic compounds, having an aromatic structure like lignin, has become a subject of extensive research.
BIODEGRADING CAPABILITY OF WRF
In 1985 it was demonstrated that Ph. chrysosporium was able to degrade, besides lignin macromolecules, many types of organopollutants such as polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls and dioxins, chlorophenols and chlorolignins, nitroaromatics, synthetic dyes, and diff erent pesticides. Logically, the degrading ability of other species of WRF was tested as well very soon after. Several powerful degraders-e.g., Phanerochaete sordida (P.Karst.)J.Erikss., Pleurotus ostreatus ( Jacq.:Fr.)P.Kumm., Trametes versicolor (L.:Fr.) Lloyd, Nematoloma frowardii (Speg.)E.Horak, and Irpex lacteus (Fr.)Fr.-were selected; however, the screening was mostly performed using liquid culture media.
BIODEGRADATION IN SOIL
In soil conditions the fungal degrading potential of WRE is only one prerequisite. Other factors, such as the ability of fungal mycelium to colonize soil matrix, its resistance to autochthonous soil microfl ora and to the toxic compounds present in polluted soils, as well as the eff ect of physicochemical parameters of the respective soil, will be discussed in the lecture.
Step-by-step selection of a fungal degrader will be demonstrated using the model fungus Irpex lacteus. Provided that the respective fungal strain significantly decreased the content of the respective pollutant in the soil under laboratory conditions and, simultaneously, that applied ecotoxicological tests also documented the decrease in soil toxicity, the process can be scaled up.
SCALE-UP AND FIELD APPLICATIONS
Large-scale production of fungal inoculum does not represent a special problem; the inoculum (i.e., lignocellulosic material such as straw, sawdust, and wood chips colonized with fungal mycelium) can be
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Institute of Microbiology, Academy of Sciences of the Czech Republic, Videnska 1083, CZ-14220 Prague 4, Czech Republic produced using facilities of a local oyster mushroom (Pleurotus spp.) or shiitake (Lentinus edodes) farm. In case of a long distance between a mushroom farm and the decontamination site, a solid-state fermentor can be used; for a very long distances the inoculum in the form of alginate-gel pellets can be prepared. Landfarming, biopiling, or treatment in containers are frequently used techniques in soil remediation. All the approaches are based on the same principle-mixg the contaminated soil with lignocellulosic substrate colonized with fungal mycelium and allowing it to work for several weeks or months under proper environmental conditions. Experience in large-scale soil mycoremediation gained in the Czech Republic, the USA, and Germany will be evaluated in the lecture.
PROBLEMS, ADVANTAGES, AND PERSPECTIVES
Mycoremediation, similar to most of other bioremediation approaches, has some drawbacks: the process is usually slow, and the removal of contaminants is rarely close to 100%. Th e soil matrix and bioavailability of the respective pollutant infl uence the fi nal result of the treatment. However, compared to physical or chemical treatments, bioremediation is environment friendly and is a cost-eff ective approach. On one hand, specifi c features of mycoremediation are that no special equipment is needed for inoculum production (sometimes even a spent oyster mushroom substrate can be used as inoculum), and for the soil treatment, standard agricultural machinery can be used. Th e other advantage of mycoremediation is that the soil treated with this procedure is biologically sound and active; fungal mycelium and its career (straw, wood chips) is converted to humus, and after the decomposition of the substrate, the introduced ligninolytic fungus is not able to compete with the newly revived soil microfl ora and dies off naturally. On the other hand, in several cases, the degradation can be unsuccessful, and thus the process has not yet become a reliable environmental biotechnology.
In conclusion, the future success of myco remedia tion depends on more intensive research into bioremediation generally and more extensive research into the biodegrading potential, physiological properties, and ecology of a large number of white rot and litter-decomposing fungi. Upon submitting more than a hundred in vitro cultures of mushrooms to the US Defense Department's Bioshield BioDefense program, several tests show that some of these polypore mushrooms have strong antiviral activity. Within these verdant natural landscapes, trees hundreds of years old host ancestral strains of these elusive polypores. Species that are now rare, or in some cases thought to be extinct, still reside in the pristine old growth forests of the Pacifi c Northwest of North America. When clones from these mushrooms were grown in vitro and submitted for antiviral screening, several mycelial cultures produced antibiotics eff ective against Pox and other viruses. Notably, strains vary in their antiviral properties. Our natural genomes hold within them great potentials for staving off disease and have not yet been fully explored. Th e fungal diversity within these genomes may prove critical for isolating the most active strains, similar to the lessons learned from the isolation of Penicillium chrysogenum strains that lead to the commercialization of penicillin and saved millions of lives.
With deforestation, pollution, and industrialization, societies should reevaluate the importance of their natural forests in the context that they hold within them novel medicines of enormous socioeconomic importance. Th e old paradigm of viewing the forest as valuable only in terms of timber seems overly simplistic given this new knowledge. Th e number of mushrooms on Earth is estimated at 140,000, yet perhaps only 10% (approximately 14,000 named species) are known. Edible higher Basidiomycetes are being evaluated for their nutritional value and acceptability, as well as their pharmacological properties. Th ey make up a vast and yet largely untapped source of powerful new pharmaceutical products. In particular, and most importantly for modern medicine, they present an unlimited source of polysaccharides with anticancer and immunostimulating properties. Many, if not all, Basidiomycetes mushrooms contain biologically active polysaccharides in their fruit bodies, cultured mycelia, and culture broth.
Th e data about mushroom polysaccharides are summarized for 651 species and seven intraspecifi c taxa from 182 genera of higher Hetero-and Homobasidiomycetes. Th ese polysaccharides are of diff erent chemical composition; the main ones comprise the group of β-glucans. β-(1→3) linkages in the main chain of the glucan and further β-(1→ 6) branch points are needed for their antitumor action. Numerous bioactive polysaccharides or polysaccharide-protein complexes from medicinal mushrooms are described that appear to enhance innate and cell-mediated immune responses and exhibit antitumor activities in animals and humans.
Stimulation of host immune defense systems by bioactive polymers from medicinal mush- Many of them are not strictly pharmaceutical products (real medicines) but represent a novel class of dietary supplements (DSs) or "mushroom nutriceuticals." Th e agents derived from medicinal mushroom fruit bodies, cultured mycelium, and/or culture fi ltrates exert a wide range of benefi cial biological eff ects when tested in vitro or using animal models. Recent years have seen a surge of commercial interest in medicinal mushroom DSs, the common market value of which is approximately $13 billion US dollars.
Th e safety advantages of using mushroom-based DSs, as opposed to herbal preparations are the following. (1) Th e overwhelming majority of mushrooms used for production of DSs are cultivated commercially (and not gathered in the wild); this provides a very good chance of proper identifi cation, and pure and unadulterated products. In many cases it also means genetic uniformity. (2) Mushrooms are easily propagated vegetatively and thus keep to one clone. Th e mycelium can be stored for a long time, and the genetic and biochemical consistency may be checked after considerable time. (3) Th e main advantage, in our opinion, is that many mushrooms are capable of growing in the form of mycelia biomass in submerged cultures.
BACKGROUND
In the course of our search for new drug candidates from polypores, we studied a rare North American mushroom, Merulius incarnatus (Corticiaceae). Th e polypores and corticioid fungi are members of Aphyllophorales, a group of morphologically complex, terrestrial Basidiomycetes. Many of these fungi are saprobic wood decayers and most often are found on logs, stumps, or other dead wood. Polypores are considered by many as a major source of pharmacologically active natural products. Th eir secondary metabolites exhibit a wide range of biological activities such as antimicrobial, antiviral, antifungal, anticancer, cardiovascular, anti-infl ammatory, antioxidant, immunostimulating, nematocidal, and other activities (Zjawiony, 2004) .
Merulius incarnatus Schwein. (1822), also known under the later name Phlebia incarnata Nakesone et Bursdall (1994) , can be found on dead logs and stumps of hardwoods, particularly those of white oak, beech, maple, and birch in the southeastern United States. It grows in overlapping clusters, usually with Stereum ostrea (Blume et T.Nees) Fr., mostly in the fall months (September-November). M. incarnatus is a rather small mushroom (2-5 cm in diameter), with a very characteristic bright coral pink color of the upper cap-hence, the common name Coral Woodcrust. Th e fruiting body is irregularly shaped, elliptical or semicircular, slightly convexed without stem. Th e pore surface is whitish and veined. Th e spores are white, elliptical, and 2-4 µm in diameter. Th e mushroom gives the yellow to orange test reaction with KOH.
MATERIALS AND METHODS
We collected M. incarnatus in the fall of 2001, 2002, and 2003 at Duke Forest in Durham, North Carolina. Fruiting bodies were extracted fresh with 95% ethanol and subjected to chromatographic separation, using standard and argented column chromatography followed by HPLC on Waters Delta Prep 4000 system using reverse phase Symmetry-C₈, 5 µm column, eluting with isocratic solution of . Antimicrobial assays were conducted at the microbiological laboratories of the National Center for Natural Products Research against following pathogens: Candida albicans, C. glabrata, C. krusei, Cryptococcus neoformans, Aspergillus fumigatus, Mycobacterium intracellulare, Staphylococcus aureus, and methacilin resistant S. aureus (MRSA).
RESULTS
A crude extract of Merulius incarnatus exhibited signifi cant activity against several microorganisms, particularly Staphylococcus aureus and methacillin resistant S. aureus (MRSA) . Th e most active fraction showed IC₅₀ = 3.5 µg /mL against MRSA. Th ese results prompted us to do further studies on isolation and structure elucidation of active secondary metabolites from this mushroom. Th e series of resorcinol (A) and resorcinolic acid (B) derivatives substituted with a long (C15 and C17) saturated and unsaturated aliphatic chain were obtained. For each series of derivatives (A and B) we were able to isolate seven compounds with 0, 1, 2, or 3 double bonds in the side chain.
Merulius incarnatus
DISCUSSION
Isolation of series of resorcinol and resorcinolic acid derivatives substituted with a long saturated and unsaturated aliphatic chain makes it the fi rst and yet not published example of work on identifi cation of secondary metabolites from Merulius incarnatus. Fıve compounds isolated are new and have never been found in any species. Other compounds isolated such as merulinic acid A, D, and E have been found in other mushroom species such as Merulius tremellosus Schrad. and Hapalopilus mutans (Peck) Gilb. et Ryverden (Giannetti et al., 1978; Sontag et al., 1999) . Some resorcinol derivatives isolated from M. incarnatus are also known as the components of cereal grains (Kozubek and Tyman, 1999) . All resorcinolic acid derivatives exhibited selective antimicrobial activity against methacillin resistant Staphylococcus aureus.
Th e structural similarity of all isolated compounds within a particular series made the separation and isolation process extremely challenging. It required the use of vacuum liquid chromatography (VLC), argented column chromatography (ACC), and reverse phase high performance liquid chromatography (HPLC), and in the cases of resorcinolic acid also a chemical modifi cations. Th e fact of the isolation of compounds with cis-trans conjugated system is unprecedented. We believe that these compounds are formed by enzymatic or photochemical isomerization in vivo. Further studies to understand the mechanism of formation and biological role of these compounds are needed. (Kozubek and Tyman, 1999) . They have either one or two double bonds in a cis confi guration, and in some cases, also the terminal double bond. (B) The compounds with cis-trans conjugated system in place of isolated cis-cis were also isolated (C).
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